and Related Infections, United States, 2017. Open Forum Infect Dis. 2018 Jul;5(7):ofy132. \[[PMC free article: PMC6041812](/pmc/articles/PMC6041812/)\] \[[PubMed: 30018999](https://pubmed.ncbi.nlm.nih.gov/30018999)\] 14. Beeler C, Dbeibo L, Kelley K, Thatcher L, Webb D, Bah A, Monahan P, Fowler NR, Nicol S, Judy-Malcolm A, Azar J. Assessing patient risk of central line-associated bacteremia via machine learning. Am J Infect Control. 2018 Sep;46(9):986-991. \[[PubMed: 29661634](https://pubmed.ncbi.nlm.nih.gov/29661634)\] 15. Morrison T. eNews Tool to Prevent Central Line-Associated Bloodstream Infection. Comput Inform Nurs. 2018 Apr;36(4):161-165. \[[PubMed: 29620619](https://pubmed.ncbi.nlm.nih.gov/29620619)\] 16. Mogle BT, Steele JM, Seabury RW, Dang UJ, Kufel WD. Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia. Int J Antimicrob Agents. 2018 Dec;52(6):805-810. \[[PubMed: 30176357](https://pubmed.ncbi.nlm.nih.gov/30176357)\] 17. Chen SY, Lee H, Wang XM, Lee TF, Liao CH, Teng LJ, Hsueh PR. High mortality impact of Staphylococcus argenteus on patients with community-onset staphylococcal bacteraemia. Int J Antimicrob Agents. 2018 Dec;52(6):747-753. \[[PubMed: 30149137](https://pubmed.ncbi.nlm.nih.gov/30149137)\] 18. Bidell MR, Patel N, O'Donnell JN. Optimal treatment of MSSA bacteraemias: a meta-analysis of cefazolin versus antistaphylococcal penicillins. J Antimicrob Chemother. 2018 Oct 01;73(10):2643-2651. \[[PubMed: 30085140](https://pubmed.ncbi.nlm.nih.gov/30085140)\] **Disclosure:** David Smith declares no relevant financial relationships with ineligible companies. **Disclosure:** Sara Nehring declares no relevant financial relationships with ineligible companies.